Sweeny Nicole reported option exercise involving 6,250 shares of KalVista Pharmaceuticals, Inc. on May 21, 2026

Option exercise
Form 4 code M. Exercise or conversion of a derivative security exempt under Rule 16b-3.
Chief Commercial Officer
Chief Commercial Officer
Filed May 26, 2026

Facts from the filing

Form 4 · Non-derivative, table I
Disclosed value
—Shares × reported price
Shares traded
6,250Common Stock
Price per share
Price unknownReported price. Read footnotes for ranges.
% of reported position traded
UnavailableThis security and ownership context
Holdings after
57,641Direct
Trade date
May 21, 2026Option exercise
Filed
May 26, 2026, 7:34 PM ET5-day reporting delay
Accession
0001827505-26-000004Code M · Transaction 384318
How reported position traded is calculated

Calculated only for code-P purchases and code-S sales.

Row-level estimate for this security and ownership context, not the insider’s complete portfolio. Joint ownership, other transactions in the filing, amendments and footnotes can affect interpretation.

Other trades in this filing

Trade dateActivitySharesPriceValueDetails
May 21, 2026Option exercise6,250$0.00$0Trade 384320
May 22, 2026Sell1,861$26.78−$49,845.77Trade 384319
3 transaction rows in this filing. Joint filers share the same rows.

Filing warnings

Notes recorded with this filing
1 warning
missing priceThe filing did not provide a usable price per share.

KALV price since this filing

Daily closing prices, with the filing date and available return windows. Return methodology
KALV · Daily closing priceDaily price data is pending. The chart appears when valid daily closes are available.
Filing dateReturn windows appear as prices become available.
Pre-filing1mo ago −28%1w ago −0.2%1d ago 0%
Returns since7d +0.5%30d +0.7%90d +0.7%180d1y

Footnotes in full

F1: Each restricted stock unit ("RSU") represents a contingent right to receive 1 share of the Issuer's Common Stock upon settlement for no consideration. F2: The sale reported on this Form 4 represents shares sold by the Reporting Person to cover tax withholding obligations in connection with the vesting and settlement of RSUs. The sale was to satisfy tax withholding obligations to be funded by a "sell to cover" transaction and does not represent a discretionary transaction by the Reporting Person. F3: 1/16th of the total number of shares subject to the RSU shall vest on each quarterly anniversary of the Vesting Commencement Date commencing on May 21, 2025, subject to continued service through each vesting date.